Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy

Affiliations

• ¹ School of Medicine, University of South Carolina, Columbia, SC, United States.
• ² Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, United States.
• ³ Sleep and Wake Disorders Centre, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France.
• ⁴ Department of Neurology, University of Montpellier, INSERM U1061, Montpellier, France.
• ⁵ Helsinki Sleep Clinic, Vitalmed Research Center, Helsinki, Finland.
• ⁶ Neurophysiology and Sleep Disorders Unit, Hospital Vithas Nuestra Señora de America, Madrid, Spain.
• ⁷ Sleep Disorders Center, Cleveland Clinic, Cleveland, OH, United States.
• ⁸ Global Clinical Development, Jazz Pharmaceuticals, Inc., Palo Alto, CA, United States.
• ⁹ Biostatistics, Jazz Pharmaceuticals, Inc., Palo Alto, CA, United States.
• ¹⁰ Department of Neurology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.